GEO series
SIRT2 deacylase modulators control B cell metabolic reprogramming in EBV infection and mitogenic activation
GSE342301
Homo sapiens
Expression profiling by high throughput sequencing
8 samples
Submitted 2026/08/06
Platform GPL24676
Summary
Sirtuin-2 (SIRT2) is a cellular deacylase, regulating cell cycle progression and metabolic homeostasis. Recently, SIRT2 has emerged as a target with both anticancer and antiviral potential. However, the role and targetability of SIRT2 in viral-driven cancers remains unexplored. Epstein-Barr virus (EBV) is a ubiquitous herpesvirus with oncogenic potential that establishes latency in B lymphocytes and is typically controlled by a robust T cell immune response. In settings that compromise this response, such as immune suppression following transplant, EBV can cause B cell lymphomas. With broad immunosuppression and varying response rates limiting the effectiveness of existing lymphoma therapeutics, new strategies are necessary. SIRT2 modulation significantly alters gene expression and metabolism of EBV-infected B cells. Treatment with SIRT2 modulators drives hyperacetylation of targets involved in lipid metabolism, central carbon metabolism, and oxidative phosphorylation. EBV-positive and EBV-negative B cell lymphomas rely on glycolysis to avoid cell death after SIRT2 modulation, revealing a metabolic vulnerability that can be harnessed to kill lymphoma cells. Overall, we have identified how SIRT2 could be implicated as a novel target of therapeutic potential for B cell lymphomas, while also defining fundamental roles for extranuclear lysine acetylation in regulating B cell proliferation and metabolism.
This dataset
Download
Direct links to NCBI, no account and no request form: the whole study as GSE342301_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 8 samples. Raw sequencing reads are also available from ENA.
Also filed as BioProject PRJNA1507326. Searching any of these in the dataset finder brings you back here.
Study design
8 conditions, each sampled once — no replicated groups
Read from 8 sample titles: 8 distinct titles with little repetition. Check it against the sample list below before relying on it.
Samples in this study
0 selected
- GSM9927674 LCL 44 treated with DMSO 24 hours
- GSM9927675 LCL 44 treated with DMSO 48 hours
- GSM9927676 LCL 45 treated with DMSO 24 hours
- GSM9927677 LCL 45 treated with DMSO 48 hours
- GSM9927678 LCL 44 treated with FLS-359 24 hours
- GSM9927679 LCL 44 treated with FLS-359 48 hours
- GSM9927680 LCL 45 treated with FLS-359 24 hours
- GSM9927681 LCL 45 treated with FLS-359 48 hours
Similar datasets
- GSE273700 Whole transcriptome analysis reveals T cell signaling activation in septic patients with thrombocytopenia 104 samples
- GSE341139 A conserved HAND2-BMP5-SMAD1/5/9 axis drives hepatic stellate cell activation and extracellular matrix overproduction in multiple fibrotic etiologies 10 samples
- GSE314342 Genome-scale perturb-seq in primary human CD4+ T cells reveals genes regulating T cell programs and human immune traits. 577 samples
- GSE205672 Transcriptomes of human PBMCs and monocytes in sepsis patients 460 samples
- GSE319641 RNA-Seq profiling of pre- and on-treatment tumor samples from breast cancer patients enrolled in the NeoTRIP trial. 401 samples
- GSE309595 Longitudinal Analysis of Multiple Myeloma: Therapeutic Response and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity [scRNA-seq] 270 samples
- GSE243013 A single-cell atlas of immune heterogeneity in anti-PD1-treated non-small cell lung cancer 243 samples
- GSE263733 Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications 218 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.